In this role, Mr. Ji will lead BioDuro’s global chemistry, manufacturing and controls (CMC) organisation, driving strategic planning, operations, and the continued expansion of the company’s development and manufacturing capabilities.
Mr. Ji brings nearly two decades of leadership experience across leading global pharmaceutical companies and CDMOs, including Roche US, Novartis CN, WuXi STA (a CDMO subsidiary of WuXi AppTec), and Porton Pharma Solutions. Most recently, he served as Senior Vice President & General Manager of Porton’s global small-molecule CDMO business, where he led a USD 300 million division with over 1,500 employees across the U.S., Europe, and China. Under his leadership, the division achieved a three-year compound annual growth rate (CAGR) of more than 50% through the successful execution of a strategic expansion plan.
In addition to driving rapid commercial growth, Mr. Ji played a pivotal role in transforming Porton from a traditional CMO to a fully integrated CDMO, building a world-class technology platform with over 100 scientists and engineers.
Yaohui brings an exceptional combination of scientific depth, operational excellence, and strategic vision,
Armin Spura, Chief Executive Officer of BioDuro. “His proven track record in scaling global CDMO operations and driving innovation will further strengthen our CMC capabilities and accelerate our mission to deliver integrated drug development to our clients worldwide.”
Mr. Ji holds a Master’s from Brown University, Rhode Island, and a Bachelor’s from the University of Science and Technology of China, Hefei. He holds three international patents and has authored multiple journal articles in the fields of pharmaceutical R&D and compliance management.